Pulmonary Arterial Hypertension Clinical Trials

Researchers in the Duke Division of Pulmonary, Allergy, and Critical Care Medicine are devoted to understanding the causes and mechanisms of pulmonary arterial hypertension. We are conducting a number of trials to test treatment options and medicines to combat this disease.

Current Clinical Trials

Select a trial to read the full description on the clinicaltrials.gov Web site:

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) (ASC01): The primary objective of this study is to compare patients with scleroderma-related PAH treated with rituximab to those on placebo for change in pulmonary vascular resistance (PVR) as assessed by right heart catheterization.

Principatl Investigator: Victor Tapson, MD

 

A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2): This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). 

Principal Investigator: Victor Tapson, MD

 

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) (Compass 2): This study will investigate the effects of the combination of bosentan and sildenafil. Patients with symptomatic PAH treated with a stable dose of sildenafil equal to or greater tha 20 mg t.i.d. for at least 12 weeks will be randomized to placebo or bosentan 125 mg b.i.d. 

Principal Investigator: Victor Tapson, MD

 

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic: The purpose of this eight-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.

Principal Investigator: Victor Tapson, MD

 

Enroll in a Pulmonary Clinical Trial at Duke

Researchers in our division are investigating a variety of treatments and therapies to respond to lung disease. Click here for a list of current clinical trials.